What is the purpose of this clinical study?
The purpose of this phase 3 clinical study is to measure overall survival (OS), progression-free survival (PFS) and safety of ivonescimab when combined with chemotherapy compared to pembrolizumab combined with chemotherapy. (OS: The amount of time after the start of a treatment that patients diagnosed are still alive. PFS: The length of time during and after the treatment that a patient lives with the disease and it does not get worse.)
What is the clinical study drug, ivonescimab?
Ivonescimab is an investigational treatment which may block two separate targets in the body; blocking these targets may decrease the cancer cells ability to live, grow, and spread.
Are you eligible for this clinical study?
You may be eligible if you have been diagnosed with metastatic (cancer that has spread) NSCLC and you have not received any prior therapy for NSCLC in the metastatic setting. You cannot have any genetic mutations which include EGFR, ALK, ROS1 or BRAF V600E.
Please talk with your doctor to determine if you are eligible.
If you are eligible, what is involved?
Your doctor can provide you with additional information but here are a few things to know:
- Once enrolled in the clinical study, you will visit the clinic every three weeks for infusions.
- You will receive regular blood tests and scans of your tumor.
- You will be regularly asked about any side effects or safety concerns you have.
If you are in the clinical study, will you receive ivonescimab?
You will be randomly assigned to one of two treatment groups.
Half the patients will be assigned to receive ivonescimab and chemotherapy and the other half will receive pembrolizumab and chemotherapy.
How are the drugs administered?
Ivonescimab, chemotherapy, and pembrolizumab are administered by infusion (medication delivered into the body through the bloodstream instead of taking by mouth such as pills or liquid).